Novo Nordisk says more patients can start taking Wegovy after it boosts supply

By RockedBuzz 2 Min Read


Michael Siluk

Novo Nordisk stated on Wednesday that it has elevated the supply of the bottom dose of its blockbuster weight reduction drug Wegovy, which it says will enable more individuals within the US to start taking the drug.

Last May, because of excessive demand for the drug, Novo Nordisk restricted the supply of the bottom dose of Wegovy, often known as the preliminary dose, to keep away from a scarcity of upper doses.

Because the medicine can include gastrointestinal unintended effects, resembling nausea and vomiting, medical doctors usually start new patients on the bottom dose after which progressively improve the dose over a number of weeks.

Due to Novo Nordisk’s supply constraints – an try to take care of enough supply for individuals already on the load loss drug – many new patients had been unable to start remedy.

In addition, some individuals who needed Wegovy prescribed Ozempic e-label as an alternative for weight reduction, which meant that folks with diabetes couldn’t get their medicine. (Ozempic, additionally from Novo Nordisk, is authorized for diabetes and shares the identical lively ingredient as Wegovy, known as semaglutide.)

Novo Nordisk made the announcement throughout a name with reporters discussing its 2023 monetary outcomes.

He added that insurance coverage protection of the load loss drug continues to enhance.

About 50 million individuals within the US who’re overweight ought to be capable to get protection for Wegovy, based on the corporate.

Share This Article
Leave a comment